CRIS Current Research Information System

MOLLICA, VERONICA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.317
EU - Europa 1.300
AS - Asia 319
AF - Africa 99
Continente sconosciuto - Info sul continente non disponibili 1
Totale 3.036
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.312
IT - Italia 408
SE - Svezia 251
GB - Regno Unito 130
DE - Germania 123
CH - Svizzera 112
VN - Vietnam 96
IN - India 90
IE - Irlanda 85
CN - Cina 64
CI - Costa d'Avorio 51
FI - Finlandia 51
BG - Bulgaria 42
JO - Giordania 31
TG - Togo 28
FR - Francia 27
RU - Federazione Russa 27
NL - Olanda 12
NG - Nigeria 9
PL - Polonia 8
JP - Giappone 7
TR - Turchia 7
ZA - Sudafrica 6
PK - Pakistan 5
UA - Ucraina 5
AT - Austria 4
BD - Bangladesh 4
CA - Canada 4
HU - Ungheria 4
BE - Belgio 3
HK - Hong Kong 3
KR - Corea 3
PS - Palestinian Territory 3
EE - Estonia 2
EG - Egitto 2
GH - Ghana 2
MY - Malesia 2
PT - Portogallo 2
RS - Serbia 2
AE - Emirati Arabi Uniti 1
ES - Italia 1
EU - Europa 1
MX - Messico 1
RO - Romania 1
SA - Arabia Saudita 1
SC - Seychelles 1
SG - Singapore 1
UZ - Uzbekistan 1
Totale 3.036
Salva come PNG Salva come JPEG
Città #
Chandler 168
Bern 111
Fairfield 109
Southend 107
Bologna 101
Dublin 85
Ashburn 83
Princeton 61
Abidjan 51
Seattle 50
Turin 46
Milan 43
Houston 42
Sofia 42
Helsinki 40
Woodbridge 40
Cambridge 38
Wilmington 34
Boydton 33
Amman 31
Dong Ket 28
Lomé 28
New York 26
Ann Arbor 24
Beijing 21
Redmond 20
Berlin 19
Florence 18
Des Moines 13
Los Angeles 13
Redwood City 12
Bühl 11
Lappeenranta 11
Rome 11
Paris 10
Abeokuta 9
Boardman 9
San Diego 9
Westminster 9
Arezzo 7
Monzuno 7
Warsaw 7
Brescia 6
Falls Church 6
Telgate 6
Verona 6
Izmir 5
San Polo di Torrile 5
Amsterdam 4
Budapest 4
Enschede 4
Frankfurt am Main 4
Kumar 4
Mülheim 4
Nanjing 4
Olalla 4
Rimini 4
Bangalore 3
Bari 3
Brussels 3
Cardiff 3
Columbus 3
Council Bluffs 3
Genoa 3
Halhul 3
Hangzhou 3
London 3
Montechiarugolo 3
Montefalco 3
Moscow 3
Naples 3
Norwalk 3
Novosibirsk 3
Saint Petersburg 3
San Jose 3
Sant'Agata Bolognese 3
Santerno 3
Shenyang 3
Tianjin 3
Vienna 3
Zhengzhou 3
Accra 2
Bathinda 2
Cagliari 2
Cairo 2
Chiswick 2
Deiva Marina 2
Fulham 2
Gatineau 2
Guangzhou 2
Gujrat 2
Hebei 2
Hong Kong 2
Hyderabad 2
Istanbul 2
Jinan 2
Jolanda Di Savoia 2
Kilburn 2
Knivsta 2
Lahore 2
Totale 1.817
Salva come PNG Salva come JPEG
Nome #
A case of complete response to nivolumab after long-term progression-free survival with tyrosine kinase inhibitor. 161
Specific Toxicity of Maintenance Olaparib Versus Placebo in Advanced Malignancies: A Systematic Review and Meta-analysis 151
Clinical management of a pituitary gland metastasis from clear cell renal cell carcinoma. 138
ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors—A systematic review and meta-analysis of real world data 110
New Hormonal Agents in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Meta-Analysis of Efficacy and Safety Outcomes. 95
Broad spectrum mutational analysis of chromophobe renal cell carcinoma using next-generation sequencing 95
A Meta-Analysis Evaluating Clinical Outcomes of Patients with Renal Cell Carcinoma Harboring Chromosome 9P Loss. 89
The human microbiota and prostate cancer: Friend or foe? 80
Is There a Role for Immunotherapy in Prostate Cancer? 76
How to choose between percutaneous transhepatic and endoscopic biliary drainage in malignant obstructive jaundice: An updated systematic review and meta-analysis 63
Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System 61
Improving IMDC Prognostic Prediction Through Evaluation of Initial Site of Metastasis in Patients With Metastatic Renal Cell Carcinoma 61
Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience 61
Impact of HER2 assessment by CISH in urothelial carcinoma: A retrospective single-center experience 58
Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors 51
Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study 51
The functioning side of the pancreas: a review on insulinomas 50
Renal Tumors with Oncocytic and Papillary Features: A Phenotypic and Genotypic Study 50
Multi-Gene Next-Generation Sequencing Panel for Analysis of BRCA1/BRCA2 and Homologous Recombination Repair Genes Alterations Metastatic Castration-Resistant Prostate Cancer 48
Systemic Treatment for Metastatic Hormone Sensitive Prostate Cancer: A Comprehensive Meta-Analysis Evaluating Efficacy and Safety in Specific Sub-Groups of Patients 47
Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: A meta-analysis 46
Third-and later-line treatment in advanced or metastatic gastric cancer: A systematic review and meta-analysis 45
The (Eternal) Debate on Microwave Ablation Versus Radiofrequency Ablation in BCLC-A Hepatocellular Carcinoma 43
Oncology clinical trials in the time of COVID-19: How a pandemic can revolutionize patients' care 42
Platinum-based adjuvant chemotherapy for upper tract urothelial carcinoma: a change of paradigm? A meta-analysis of aggregate data 41
Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials 40
H&E and OCT4/CD34 for the assessment of lympho-vascular invasion in seminoma and embryonal carcinoma 39
A preliminary study investigating the detection of lymphovascular invasion in germ cell tumors of the testis with double staining for OCT4/CD34 39
Exploring the association between metastatic sites and androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer patients: A meta-analysis of prospective clinical trials 37
SOX2 and PRAME in the "reprogramming" of seminoma cells 36
Tumor growth rate decline despite progressive disease may predict improved nivolumab treatment outcome in mrcc: When recist is not enough 36
Immunohistochemical Expression of Preferentially Expressed Antigen in Melanoma (PRAME) in the Uninvolved Background Testis, Germ Cell Neoplasia in Situ, and Germ Cell Tumors of the Testis 34
Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials 32
Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: A systematic review 31
Microbiota and prostate cancer 29
The molecular characteristics of non‐clear cell renal cell carcinoma: What’s the story morning glory? 29
FoxA2 is a reliable marker for the diagnosis of yolk sac tumour postpubertal-type 27
Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw 26
Bone targeting agents in patients with metastatic prostate cancer: State of the art 26
Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis 25
A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy 23
Adjuvant therapy in renal cell carcinoma: Is it the right strategy to inhibit VEGF? 23
Encephalic Leukocytoclastic Vasculitis during Treatment with Sunitinib for Renal Cell Carcinoma: A Case Report 22
null 22
Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis 21
Mutations of NOTCH Genes as an Alternative Mechanism to Activate mTOR pathway in Low-grade Oncocytic Tumor (LOT) of the Kidney 21
A brand-new CAR for macrophages: Is it time to fire up the engines of a new era for the treatment of renal cell carcinoma? 20
Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis 20
TAMs PD-L1(+) in the reprogramming of germ cell tumors of the testis 20
The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System 20
TNM staging towards a personalized approach in metastatic urothelial carcinoma: What will the future be like?-a narrative review 20
Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study 19
Yolk sac tumor of postpubertal-type does not exhibit immunohistochemical loss of SMARCB1/INI1 and SMARCA4/BRG1…but choriocarcinoma? 19
Towards a new WHO classification of renal cell tumor: What the clinician needs to know-a narrative review 18
Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 study 17
Adjuvant therapy in renal cell carcinoma-is pharmacogenomics assessment another element to select our patients? 17
Adapting to hormone-therapy resistance for adopting the right therapeutic strategy in advanced prostate cancer 17
Cabazitaxel in metastatic prostate cancer 17
A meta-analysis on overall survival and safety outcomes in patients with nonmetastatic castration-resistant prostate cancer treated with novel hormonal agents 17
Adjuvant immunotherapy in muscle-invasive urothelial carcinoma 16
Metabolomic profiling in renal cell carcinoma patients: News and views 15
The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study 15
An insight on novel molecular pathways in metastatic prostate cancer: A focus on ddr, msi and akt 15
Renal Toxicities in Cancer Patients Receiving Immune-Checkpoint Inhibitors: A Meta-Analysis 15
Adjuvant treatment in renal cell carcinoma: a never-ending story? 14
Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics 14
Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma 14
The Impact of Concomitant Proton Pump Inhibitors on Immunotherapy Efficacy Among Patients with Urothelial Carcinoma: A Meta-Analysis 14
Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy 14
The dilemma of neoadjuvant and adjuvant therapy in urothelial carcinoma: Will immunotherapy solve the problem? 13
An up-to-date evaluation of cabozantinib for the treatment of renal cell carcinoma 13
Risk of toxicity with immunotherapy-tyrosine kinase inhibitors for metastatic renal cell carcinoma: a meta-analysis of randomized controlled trials 13
Cancer immunotherapy: Current and future perspectives on a therapeutic revolution 13
Adjuvant immunotherapy in muscle-invasive urothelial carcinoma 13
Evaluation of an institutional series of low-grade oncocytic tumor (LOT) of the kidney and review of the mutational landscape of LOT 13
Adjuvant Nivolumab in Muscle-Invasive Urothelial Carcinoma 12
Broad spectrum mutational analysis of chromophobe renal cell carcinoma using next-generation sequencing 12
TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab 11
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study 11
Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer 11
Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers 11
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis 10
Pembrolizumab plus enfortumab vedotin in urothelial cancer 10
Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study 10
Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis 10
Determinants of treatment for first-line immune-based combinations in metastatic renal cell carcinoma: A critical overview of recent evidence 9
Apalutamide or enzalutamide in castration-sensitive prostate cancer: a number needed to treat analysis 9
Re: WHO Classification of Tumours, 5th Edition, Volume 8: Urinary and Male Genital Tumours 9
Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis 9
An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer 9
Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma 9
Cabozantinib for Treatment of Brain Metastases in Patients with Renal Cell Carcinoma 9
An update on safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma 8
Genomics and Immunomics in the Treatment of Urothelial Carcinoma 8
Adjuvant Tyrosine Kinase Inhibitors in Treatment of Renal Cell Carcinoma: A Meta-Analysis of Available Clinical Trials 8
The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study 8
Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations 8
Current androgen receptor antagonists under investigation for resistant prostate cancer 8
Treating prostate cancer by antibody-drug conjugates 8
Molecular mechanisms related to hormone inhibition resistance in prostate cancer 8
Totale 3.131
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15.818
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.818
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020219 8 6 0 12 21 15 20 44 34 29 17 13
2020/2021358 31 8 14 44 27 8 1 20 37 25 11 132
2021/2022533 8 15 16 36 38 22 33 62 65 25 144 69
2022/20231.438 58 99 44 82 132 179 93 94 239 55 158 205
2023/2024753 87 96 64 65 51 100 22 78 40 57 46 47
2024/202514 14 0 0 0 0 0 0 0 0 0 0 0
Totale 3.347